



AUSTRALIA
Biotech
Invest 2016

Connecting Capital with Innovation

www.australiabiotechinvest.com.au

26 - 27
October
2016

Host Industry Body Host State Partner Major Partner

AusBiotech MELBOURNE Victoria Australia 100

Melbourne Convention
Centre, Victoria, Australia

AdAlta Limited

AdAlta is focused on creating value for shareholders by developing and partnering a promising new drug it believes could address the unmet medical needs of people who suffer fibrosis.

It is doing this by pioneering a range of protein therapeutics based on shark antibodies to create unique compounds, known as i-bodies.

AdAlta's first focus is on developing a drug for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases as current therapies have very limited efficacy and there is a high-unmet global medical need.

The company will finalise its IPO mid-August 2016 and raise up to AU\$10 million to advance its therapy towards clinical development and early partnering.

